Scarlett Gillespie1, Paul M Holloway1,2, Felix Becker3, Francesca Rauzi4, Shantel A Vital2, Kirk A Taylor4, Karen Y Stokes2, Michael Emerson4, Felicity N E Gavins2,5. 1. Division of Brain Sciences, Imperial College London, London, UK. 2. Department of Molecular and Cellular Physiology, Louisiana State University Health Sciences Center - Shreveport, Shreveport, LA, USA. 3. Department of General, Visceral and Transplant Surgery, University Hospital Muenster, Muenster, Germany. 4. Platelet Biology Group, National Heart and Lung Institute, Imperial College London, London, UK. 5. Department of Neurology, Louisiana State University Health Sciences Center - Shreveport, Shreveport, LA, USA.
Abstract
BACKGROUND AND PURPOSE: Platelet activation provides a critical link between inflammation and thrombosis. Sulforaphane (SFN), a naturally occurring isothiocyanate, has been shown to display both anti-inflammatory and anti-thrombotic actions in the systemic microvasculature. As inflammation promotes thrombosis and vice versa, in this study we investigated whether SFN is able to reduce inflammatory potentiation of thrombotic events, suppress platelet activation and thrombus formation in the cerebral microvasculature. EXPERIMENTAL APPROACH: Thrombosis was induced in the murine brain using the light/dye-injury model, in conjunction with LPS treatment, with and without SFN treatment. In vitro and in vivo platelet assays (aggregation, flow and other functional tests) were also employed, using both human and murine platelets. KEY RESULTS: SFN was found to reduce LPS-mediated enhancement of thrombus formation in the cerebral microcirculation. In tail-bleed experiments, LPS treatment prolonged bleeding time, and SFN treatment was found to protect against this LPS-induced derangement of platelet function. SFN inhibited collagen-mediated platelet aggregation in vitro and in vivo and the associated adhesion and impaired calcium signalling. Furthermore, glycoprotein VI was shown to be involved in the protective effects observed with SFN treatment. CONCLUSIONS AND IMPLICATIONS: The data presented here provide evidence for the use of SFN in preventing stroke in selected high-risk patient cohorts.
BACKGROUND AND PURPOSE: Platelet activation provides a critical link between inflammation and thrombosis. Sulforaphane (SFN), a naturally occurring isothiocyanate, has been shown to display both anti-inflammatory and anti-thrombotic actions in the systemic microvasculature. As inflammation promotes thrombosis and vice versa, in this study we investigated whether SFN is able to reduce inflammatory potentiation of thrombotic events, suppress platelet activation and thrombus formation in the cerebral microvasculature. EXPERIMENTAL APPROACH: Thrombosis was induced in the murine brain using the light/dye-injury model, in conjunction with LPS treatment, with and without SFN treatment. In vitro and in vivo platelet assays (aggregation, flow and other functional tests) were also employed, using both human and murine platelets. KEY RESULTS:SFN was found to reduce LPS-mediated enhancement of thrombus formation in the cerebral microcirculation. In tail-bleed experiments, LPS treatment prolonged bleeding time, and SFN treatment was found to protect against this LPS-induced derangement of platelet function. SFN inhibited collagen-mediated platelet aggregation in vitro and in vivo and the associated adhesion and impaired calcium signalling. Furthermore, glycoprotein VI was shown to be involved in the protective effects observed with SFN treatment. CONCLUSIONS AND IMPLICATIONS: The data presented here provide evidence for the use of SFN in preventing stroke in selected high-risk patient cohorts.
Authors: Aleksandra Konić-Ristić; Tatjana Srdić-Rajić; Nevena Kardum; Vesna Aleksić-Veličković; Paul A Kroon; Wendy J Hollands; Paul W Needs; Nadiya Boyko; Osman Hayran; Mariam Jorjadze; Maria Glibetić Journal: J Sci Food Agric Date: 2013-09-04 Impact factor: 3.638
Authors: Yasser Sakr; Marc-Jacques Dubois; Daniel De Backer; Jacques Creteur; Jean-Louis Vincent Journal: Crit Care Med Date: 2004-09 Impact factor: 7.598
Authors: Andrew L Frelinger; Joseph A Jakubowski; Julie K Brooks; Sabrina L Carmichael; Michelle A Berny-Lang; Marc R Barnard; Matthew M Heeney; Alan D Michelson Journal: Platelets Date: 2013-03-07 Impact factor: 3.862
Authors: Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2017-12 Impact factor: 8.739
Authors: Simon D Harding; Joanna L Sharman; Elena Faccenda; Chris Southan; Adam J Pawson; Sam Ireland; Alasdair J G Gray; Liam Bruce; Stephen P H Alexander; Stephen Anderton; Clare Bryant; Anthony P Davenport; Christian Doerig; Doriano Fabbro; Francesca Levi-Schaffer; Michael Spedding; Jamie A Davies Journal: Nucleic Acids Res Date: 2018-01-04 Impact factor: 16.971
Authors: Scarlett Gillespie; Paul M Holloway; Felix Becker; Francesca Rauzi; Shantel A Vital; Kirk A Taylor; Karen Y Stokes; Michael Emerson; Felicity N E Gavins Journal: Br J Pharmacol Date: 2018-07-03 Impact factor: 8.739
Authors: Dina A I Albadawi; Divyashree Ravishankar; Thomas M Vallance; Ketan Patel; Helen M I Osborn; Sakthivel Vaiyapuri Journal: Int J Mol Sci Date: 2022-01-06 Impact factor: 6.208